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Abstract
Background: In view of the reduced number of hours devoted to sleep in modern western societies the question arises
what effects might result from sleep duration on occurrence of chronic diseases.
Methods: Data from 23 620 middle-aged participants of the European Prospective Investigation into Cancer and Nutrition
(EPIC)-Potsdam study, that were recruited between 1994–1998, were analyzed by using Cox proportional hazard regression
to examine the association between self-reported sleep duration at baseline and incidence of chronic diseases, such as
diabetes, myocardial infarction, stroke, and cancer.
Results: During a mean follow-up period of 7.8 years 841 incident cases of type 2 diabetes, 197 cases of myocardial
infarction, 169 incident strokes, and 846 tumor cases were observed. Compared to persons sleeping 7-,8 h/day,
participants with sleep duration of ,6 h had a significantly increased risk of stroke (Hazard Ratio (HR)=2.06, 95%
confidence interval (CI): 1.18–3.59), cancer (HR=1.43, 95% CI: 1.09–1.87), and overall chronic diseases (HR=1.31, 95% CI:
1.10–1.55) in multivariable adjusted models. Self-reported daytime sleep at baseline was not associated with incident
chronic diseases in the overall study sample. However, there had been an effect modification of daytime sleep by
hypertension showing that daytime sleep was inversely related to chronic disease risk among non-hypertensive participants
but directly related to chronic diseases among hypertensives.
Conclusion: Sleep duration of less than 6 h is a risky behavior for the development of chronic diseases, particularly stroke
and cancer, and should be therefore addressed in public health campaigns.
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Introduction
The examination of the relationship between sleep and health
has gained increasing scientific importance, especially in popula-
tion-based studies. In particular, it has been suggested that sleep is
essential for recreation, energy conservation, repair and infection
control, and that it is important for the programming of the brain
[1,2,3].
Understanding the importance of sleep is particularly relevant
as sleeping habits have been changing since the industrial age. In
our modern 24-hour a day society, the overall prevalence of sleep
disorders and daytime sleepiness is high and duration of sleep per
day tends to be decreased [3,4,5,6]. This trend is a result of less
dependency of daylight hours, increased shift-work, long working
hours [6,7,8], increased time spent commuting to and from the
workplace [7], and alterations in lifestyle. Alterations in lifestyle
may for example refer to the double burden of taking care of
family’s needs and work-related responsibilities [8]. The 2005
Sleep in America poll indicates that, on average, adults in America
are sleeping 6.9 h a night when considering both weekday and
weekend sleep. 40% of the respondents reported getting less than
7 h of sleep per night on weekdays. A large majority (75%)
reported having had at least one symptom of a sleep problem, e.g.
difficulties falling asleep, difficulties maintaining sleep, sleep-
related breathing disorders, or getting up feeling not rested, a
few nights a week or more within the past year [9].
Due to the adverse changes in sleeping habits the question arises
which long-term health consequences might result from sleep
deficiency. Emerging data suggest that sleep deprivation has major
metabolic and cardiovascular consequences and consequently
might be a risk factor for poor health in the future [3,10,11,12,13].
Habitual sleep durations of #5–6 h sleep per 24 h may lead to an
increased risk of incident diabetes [14,15,16,17,18], cardiovascular
diseases [19,20,21,22,23], and breast cancer [24]. On the other
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for incident diabetes [15,16,25,26] and cardiovascular diseases
[19,21,27] was elevated. In addition, also daytime naps are
discussed to have detrimental effects on health, e.g. on diabetes
[17] or cardiovascular risk [28]. Up to now, just a few studies
concerning this topic were conducted in Europe and in general
these studies focused on one endpoint and thus did not take into
account competing risks for different chronic disease endpoints.
Therefore, this analysis primarily aims to investigate whether
sleeping habits practiced nowadays are related to the occurrence
of the most important chronic diseases, i.e. the combination of
incident type 2 diabetes, cardiovascular diseases, and cancer,
within the European Prospective Investigation into Cancer and
Nutrition (EPIC)-Potsdam study.
Materials and Methods
Study population: the EPIC-Potsdam study
The European Prospective Investigation into Cancer and
Nutrition (EPIC) study is an ongoing large-scale cohort study on
diet and chronic diseases, especially cancer, with over half a
million participants across Europe. EPIC-Potsdam is one out of 23
centers of EPIC with 27 548 participants aged mainly 35–65 years
that had been recruited between 1994 and 1998 from the general
population of Potsdam and adjacent communities. The study
instruments of the baseline examination included a computer-
guided interview on lifestyle habits and medical history, self-
administered questionnaires on food consumption and lifestyle as
well as physical examinations performed by trained staff at the
study centre [29]. The EPIC-Potsdam study has been approved by
the Ethical Committee of the Federal State of Brandenburg.
Written informed consent for measurements and inquiries
including prospective data collection has been obtained from all
participants before joining EPIC-Potsdam.
Every 2–3 years the participants received a mailed follow-up
questionnaire to assess incident diseases, medication, and changes
in diet and other lifestyle factors. Tracing of non-responders,
reminder services, and computer programs controlling for
completeness or implausible values contribute to the generation
of valid and complete follow-up data and high response rates for
each follow-up round (93–96%) [30].
Participants with prevalent diabetes mellitus, myocardial
infarction, stroke, or cancer (all except non-melanoma skin
cancer) (n=3 130), missing follow-up time (n=589), missing data
on exposure or relevant covariates (n=207) as well as those
reporting not to sleep at all (n=2) were excluded. Thus, 23 620
participants (14 497 women and 9 123 men) remained for the
analyses. Study participants were followed up until 2007. The
follow-up time (person-years) was derived from the age at
recruitment and the age at one of the following end-points: date
of diagnoses, date of death, or return of the last follow-up
questionnaire, whichever came first.
Assessment of exposure
Participants were asked about their average duration of sleep (in
hours) at night and at day during the last 12 months with two open
questions in the baseline interview. Moreover, also sleep disorders
were assessed in the baseline interview with the following
questions: ‘‘Have you ever suffered from sleep disorders that were
treated by a physician?’’ If this question was answered with ‘‘yes’’,
participants were further asked: ‘‘How long did you suffer from
sleep disorders? Please total all periods in which you suffered from
sleep disorders.’’
Assessment of chronic diseases
Information about potential incident chronic diseases occurring
during follow-up were regularly assessed from self-reports of the
respective condition, medication use, or reasons for a reported
change in diet in the follow-up questionnaires. All potential
incident cases were verified using information of medical reports
from the treating physician, cancer registries, or death certificates
[30]. Diseases were coded based on the International Classification
of Disease (ICD-10: I21 for myocardial infarction, I60, I61, I63,
I64 for stroke, E11 for diabetes, and C00-C97 for cancer (except
C44: non-melanoma skin cancer). In case of multiple diseases, only
the first clinical event was considered for the analysis.
Statistical analyses
Sleep duration at baseline was considered as the main exposure
variable. Based on the habitual sleep duration, participants are
classified as short, long, or normal sleepers. Therefore, the sleep
duration at night and at day was summed and participants were
categorized into five groups according to their sleep duration
following the distribution of sleep duration in this cohort and cut-
offs used in former publications: ,6, 6-,7, 7-,8, 8-,9 and $9h
per 24 h (,6 h is defined as short, 6-,7 h as shortened, 7-,8ha s
normal/average, 8-,9 h as normal/prolonged and $9 h as long
sleep duration). These groups were characterized by descriptive
univariate statistics in order to examine the correlates of long and
short sleep. Baseline characteristics of the study population are
presented as arithmetic means and standard deviations (for
continuous variables) and percentages (for categorical variables).
The risk of developing a chronic disease in different groups of
sleep duration was analyzed by means of Cox proportional hazard
regression analyses. Age- and sex- as well as multivariable-adjusted
hazard ratios (HR) and 95% confidence intervals (CI) were
calculated using 7-,8 h of sleep as the reference group. This
reference was chosen for two reasons. First, 7 h of sleep had been
shown to be associated with the lowest risk of mortality [31,32,33]
and also morbidity e.g. cardiovascular disease [13] or diabetes
[12]. Second, the average sleep duration was 7 h in this sample
(mean: 7.3 h, median: 7 h).
The primary endpoint was defined as the first incident chronic
disease – i.e. type 2 diabetes, myocardial infarction, stroke, or
cancer. Additional events at a later date were not considered. The
follow-up time was defined as time period between the age of
recruitment and the age of exit (age of diagnoses, death, or
censoring). To be less sensitive against violation of the proportional
hazards assumption, all models were stratified by age. Relevant
covariates, e.g. socioeconomic and lifestyle factors were considered
by multivariable adjustment. Therefore, four models were carried
out. The first model (model 1, reduced model) was adjusted for
sex. The second model (model 2) additionally included sleeping
disorders (yes/no), alcohol intake from beverages (non-consumers;
men: 1. .0–12 g/d, 2. .12–24 g/d, 3. .24 g/d; women: 1. .0–
6 g/d, 2. .6–12 g/d, 3. .12 g/d), smoking status (never, former,
current), walking, cycling, sports (hours/week), employment status
(employed vs. unemployed), and education (university of applied
sciences or university degree vs. technical school or lower degree).
Model 3 was further adjusted for potential intermediates, i.e. BMI
(kg/m
2), waist-to-hip ratio, prevalent hypertension at baseline
(yes/no), and history of high blood lipid levels at baseline (yes/no).
Model 4 furthermore included consumption of caffeinated
beverages (coffee and black tea in g/day), satisfaction with life (4
levels: very satisfied, rather satisfied, rather dissatisfied, very
dissatisfied), satisfaction with health (4 levels: very satisfied, rather
satisfied, rather dissatisfied, very dissatisfied), and intake of
antidepressants (yes/no). Covariables were defined based on a
Sleep Duration and Chronic Diseases
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general, the same covariates were included in each model, except
baseline prevalent hypertension and higher blood lipid levels,
which were not included in the multivariable models for cancer.
In addition to sleep duration, we further investigated the effect
of timing of sleep (daytime naps (yes/no) and night-time sleep (,6,
6-,7, 7-,8, 8-,9 and $9 h)) on the risk of chronic diseases using
analogous multivariable Cox regression models.
Moreover, interactions of sleep duration (continuous) with sex,
sleeping disorders (yes/no), age (,60 vs. $60 years), alcohol
intake (category 2 and 3 vs. category 1), obesity (BMI $30 kg/m
2:
yes/no), and hypertension (yes/no) were investigated. Further-
more, interactions of these variables with daytime sleep were
examined. Therefore, models with and without interaction terms
were compared using the likelihood-ratio test. All p values were
two-sided and a significance level of p,0.05 was applied.
All analyses were performed with SAS statistical software
(release 9.2; SAS Institute Inc, Cary, North Carolina).
Results
The baseline characteristics of participants of the EPIC-
Potsdam cohort according to sleep duration are described in
Table 1. Older people, women, and individuals with less
education were more likely to report long sleep durations
($9 h). Of note, there was a relatively low proportion of employed
persons among long sleepers (34% compared to 66–78% in the
other groups) which is partly due to the relatively high amount of
(early) retired persons in this group. Furthermore, also the group of
short sleepers (,6 h) was slightly older and less high educated
compared to average sleepers.
Many health variables showed an U-shaped relation with sleep
duration, such as sleeping disorders, obesity, hypertension, and
high blood lipid levels.
There were no marked differences in intake of important food
groups between different sleep groups, except the intake of
caffeinated beverages like coffee and black tea which is linearly
inversely related to sleep duration. Therefore, food intake was not
included into the multivariate models.
Satisfaction with life was linearly associated with length of sleep
(17% were very satisfied with their life in persons sleeping ,6 h/d
compared to 28% in those sleeping $9 h/d). In contrast, U-
shaped relations were observed for other psychosocial variables
like satisfaction with health and use of antidepressants. The use of
antidepressants was especially pronounced in persons sleeping
,6 h/d (every 10
th person reported intake of antidepressants).
Table 2 shows the association of sleep duration with risk of type
2 diabetes, myocardial infarction, stroke, and cancer. During a
mean follow-up period of 7.8 years (184 388 person-years) 841
cases of incident diabetes, 197 cases of incident myocardial
infarction, 169 cases of incident stroke, and 846 incident tumor
cases occurred.
Compared to persons with habitual sleep duration of 7-,8h ,
participants reporting less than 6 h/day of sleep had an about
30% increased risk of developing overall chronic diseases in the
fully adjusted model (model 4: HR=1.31, 95% CI: 1.10–1.55)
(Figure 1 and Table 2).
Concerning specific disease outcomes, diabetes was related to
short sleep, i.e. ,6 h/day, in the model 1 as well as in model 2
(model 2: HR=1.36, 95% CI: 1.04–1.79). Further inclusion of
potential intermediates, predominantly BMI, attenuated the effect
of sleep (model 3: HR=1.08, 95% CI: 0.82–1.42). The association
between short sleep and myocardial infarction was significant in
the model 1 (HR=1.78, 95% CI: 1.07–2.97) but inclusion of
lifestyle factors, particularly smoking, attenuated this association
(model 2: HR=1.54, 95% CI: 0.92–2.59). In addition, short
sleepers had a more than 2-fold increased risk of developing stroke
compared to those sleeping 7-,8 h, independent of the kind of
model chosen (model 4: HR=2.06, 95% CI: 1.18–3.59). Short
sleep duration is also an independent risk factor for overall cancer
and consideration of several covariates did almost not change the
effect estimate (model 4: HR=1.43, 95% CI: 1.09–1.87).
However, a competing risk analysis revealed that effect estimates
for the single disease endpoints did not differ significantly from
each other. Hence, it was possible to combine all events to one
outcome called ‘‘overall chronic disease’’.
Concerning long sleep duration, no effect was observed for the
risk of chronic diseases in general, but it was shown to be
associated with an increased risk of stroke (model 4: HR for $9h /
day=1.65, 95% CI: 1.00–2.73).
We further studied the role of timing of sleep. Concerning
overall chronic disease risk the effect estimates for sleep at night
were similar to those of overall sleep duration because sleep at
night constitutes a major part of overall sleep (,6 h: HR=1.27
(1.08–1.50)) (Table S1). However, the association of ,6ho f
night-time sleep with stroke was only borderline significant after
inclusion of further covariates and sleep duration at day into the
multivariable regression model. This indicates that a slight
compensation of short night-time sleep by daytime naps might
be possible (HR=1.66 (0.97–2.86)). Furthermore, the association
of $9 h of night-time sleep with stroke was not significant (HR for
$9 h of sleep at night: 1.56 (0.89–2.75)).
Only 11.5% of participants of the EPIC-Potsdam sample were
reporting daytime sleep which had an average duration of ,1h
(mean=1.1 h). Therefore, only two exposure groups were
compared: namely persons with and without daytime naps. The
separate analysis of daytime naps revealed no influence on risk of
chronic diseases in the overall study sample. The initially
significant association of daytime napping with the risk of stroke
in the model 1 (HR=1.52 (1.04–2.24)) disappeared after
multivariable adjustment (HR=1.38 (0.93–2.03), table not
shown). Interestingly, a significant interaction of daytime naps
and hypertension in relation to chronic disease risk (p for
interaction=0.04) and cancer was observed (p for interac-
tion=0.03). Consequently, additional analyses that were strati-
fied by prevalent hypertension were conducted (Table 3).
Stratification by baseline hypertension revealed that in hyperten-
sive persons that reported to sleep during the day the risk for
overall chronic disease tends to be increased (HR=1.13 (0.98–
1.31)) which was mainly driven by stroke (HR=1.51 (0.96–2.37)).
In contrast, the risk of overall chronic disease is decreased among
non-hypertensive persons reporting daytime naps (HR=0.75
(0.59–0.96)) which is mainly due to a reduced risk for cancer
(HR=0.68 (0.49–0.95)).
Discussion
Short sleep and chronic diseases
Our results showed that, compared to average sleep (7-,8 h),
short sleep (,6 h per day) was associated with a 30% increased
risk of overall chronic disease, in particular stroke (2-fold increased
risk) and overall cancer (more than 40% increased risk).
This analysis was based on a first incident event analysis which
is a novel approach that enables to compare the effect of sleep on
different endpoints such as diabetes, cardiovascular diseases, and
cancer. There has been previous evidence that short sleep (,5–
6 h) is a habit that is associated with increased risk of chronic
diseases [3,10,11,12,13].
Sleep Duration and Chronic Diseases
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duration and diabetes risk and some of them showed that short
sleep is an independent risk factor for diabetes [14,15,16,17,18]. In
contrast, our results showed no relation between short sleep
duration and incidence of diabetes after adjustment for potential
intermediates. Similar to us, Hayashino et al. [34] and Bjo ¨rkelund
et al. [35] did not find a significant association of sleep duration
and diabetes risk. A possible reason for this discrepancy is the role
of BMI in the relationship of sleep duration and diabetes as a
potential mediator. It is often described in the literature that sleep
restriction may lead to obesity by a number of biological
mechanisms, e.g. via increased insulin resistance or via altered
secretion of hormones like ghrelin or cortisol, which in turn could
lead to subsequent diabetes [3,10,36,37]. Thus, our risk estimates
for short sleep duration as well as those of Ayas et al. [25] were
attenuated to non-significant risk estimates after adjustment for
Table 1. Baseline Characteristics and Risk Factors for Chronic Disease by Self-reported Sleep Duration.
Sleep duration ,6 h/day 6-,7 h/day 7-,8 h/day 8-,9 h/day $9 h/day
No. of subjects: 23 620 (100%) 1 242 (5.3%) 4 653 (19.7%) 9 820 (41.6%) 6 133 (26.0%) 1 772 (7.5%)
Age (years) 50.9 (8.3) 48.8 (8.4) 48.5 (8.5) 49.4 (9.3) 53.9 (9.5)
Women, % 61.7 57.9 59.5 65.6 65.9
Employed, % 67.6 78.4 78.1 66.2 33.5
(Early) retirees, % 18.7 12.7 12.7 21.3 48.2
University of applied sciences/university degree, % 29.0 40.6 41.0 35.1 25.5
Sleeping disorders, % 26.7 15.8 12.8 12.6 15.8
Obesity (BMI $30 kg/m
2), % 21.9 16.7 14.3 14.7 20.7
Prevalent hypertension, % 51.9 45.8 43.6 46.5 55.0
History of high blood lipid levels, % 32.4 24.8 23.3 24.9 32.5
Current smoker, % 25.4 23.8 19.5 18.4 21.6
Walking, cycling, sports (h/week) 11.5 (8.3) 10.4 (7.3) 10.4 (7.0) 11.0 (7.4) 12.2 (7.7)
Beverages, low-energy (g/day)
a 1 279.9 (783.7) 1 197.4 (683.6) 1 109.8 (590.9) 1 118.9 (631.0) 1 165.4 (667.0)
Beverages, high-energy (g/day)
b 248.2 (306.5) 245.0 (271.4) 232.3 (252.8) 241.7 (257.9) 252.8 (278.9)
Caffeinated beverages (g/day)
c 600.6 (442.5) 584.9 (379.2) 545.2 (332.8) 521.5 (330.2) 513.7 (335.1)
Fresh fruit (g/day) 144.4 (99.1) 142.0 (96.5) 140.0 (94.1) 143.6 (97.7) 142.0 (99.6)
Vegetables (g/day)
d 123.8 (61.9) 123.8 (59.3) 122.3 (61.0) 125.3 (59.5) 127.9 (62.1)
Whole grain bread and muesli (g/day) 50.9 (59.5) 53.2 (60.1) 50.2 (57.5) 50.7 (58.7) 46.5 (55.4)
Other bread and flakes (g/day) 133.1 (84.2) 137.8 (85.8) 130.6 (79.9) 131.7 (78.3) 124.1 (70.1)
Side dishes (g/day)
e 94.1 (52.9) 95.6 (51.5) 97.0 (49.7) 100.6 (50.7) 109.7 (51.9)
Dairy products (g/day)
f 254.5 (260.6) 236.9 (233.8) 228.2 (218.6) 229.8 (217.2) 239.5 (245.8)
Meat (g/day)
g 114.8 (74.3) 116.8 (72.1) 116.5 (66.0) 112.2 (65.5) 109.6 (65.2)
Fish (g/day) 25.3 (31.1) 23.9 (23.7) 23.2 (24.0) 23.5 (26.5) 24.1 (23.3)
Eggs (g/day) 18.5 (18.1) 18.1 (18.2) 17.6 (15.6) 17.3 (14.1) 16.9 (16.8)
Butter (g/day) 8.1 (12.8) 9.3 (13.3) 8.7 (12.5) 9.0 (12.4) 9.1 (12.5)
Vegetable oil (g/day) 3.2 (3.2) 3.4 (3.3) 3.4 (3.4) 3.5 (3.5) 3.4 (3.2)
Sweets (g/day)
h 117.5 (109.9) 114.7 (92.5) 113.9 (89.3) 112.4 (89.1) 117.5 (98.2)
Snacks (g/day)
i 22.7 (20.3) 23.9 (20.5) 24.2 (19.8) 23.2 (18.8) 21.4 (18.6)
Alcohol intake (g/day) 13.7 (19.2) 14.6 (18.0) 14.6 (17.5) 13.8 (18.4) 13.5 (23.9)
Energy intake (kJ/day) 8 999.5 (3 252.3) 9 085.3 (3 050.2) 8 879.3 (2 802.2) 8 797.4 (2 806.7) 8 761.2 (2 962.1)
Very satisfied with life, % 17.1 21.2 23.4 27.1 28.3
Very satisfied with health, % 17.6 20.5 23.0 24.2 20.0
Intake of antidepressants, % 11.0 6.3 5.0 5.2 8.1
Categorical variables are presented as percentages within the respective subgroup and continuous variables are expressed as means with standard deviation in
parentheses.
aLow-energy beverages: water, coffee (including de-caffeinated coffee), tea (including herbal tea), low-energy soft drinks (energy-reduced cola, lemonades).
bHigh-energy beverages: juice, high-energy soft drinks (cola, lemonades, non-alcoholic beer, malt beer).
cCaffeinated beverages: coffee, black tea.
dVegetables are also including legumes.
eSide dishes: pasta, rice, potatoes.
fDairy products: milk, yoghurt, curd, soured milk/kefir, cream, cheese.
gMeat: red meat, poultry, processed meat.
hSnacks: french fries, pizza, chips.
iSweets: cakes, cookies, confectionary, sweet bread spread, desserts.
doi:10.1371/journal.pone.0030972.t001
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intermediate that contribute to attenuation of the association
between sleep duration and diabetes.
Fewer studies were conducted on sleep deficiency in relation to
stroke and myocardial infarction. Chen et al. reported associations
of short sleep duration with ischemic stroke in postmenopausal
women (HR=1.14, 95% CI: 0.97–1.33 for #6 h compared to 7 h
of sleep), which became significant after exclusion of those with
baseline comorbidities like cardiovascular disease or diabetes
mellitus (HR=1.22, 95% CI: 1.03–1.44) [21]. In contrast, Amagai
et al. found no association of sleep duration and stroke after
multivariable adjustment [22] which might be due to a relative
small number of cases incorporated into this analysis. Regarding
myocardial infarction we could not identify a significant relation
with short sleep duration which is in contrast to the results of some
previous studies, e.g. the Monitoring Trends and Determinants on
Cardiovascular disease (MONICA) study [20], or the Japanese
Jichi Medical Cohort Study [22], that reported on increased risk of
myocardial infarction among women or men with short sleep. In
our analyses, the association of sleep duration and myocardial
Table 2. Hazard ratios (HR) and 95% Confidence Intervals for Type 2 Diabetes, Myocardial Infarction, Stroke, and Cancer by Sleep
Duration in the EPIC-Potsdam Cohort.
,6 h/day 6-,7 h/day 7-,8 h/day 8-,9 h/day $9 h/day
Overall chronic disease (cases/person-years)
a 162/9 282 376/36 006 790/78 263 511/47 561 203/13 276
Crude rate per 1000 person-years 17.5 10.4 10.1 10.7 15.3
HR model 1
b 1.54 (1.30–1.83) 1.02 (0.90–1.15) 1.0 1.00 (0.90–1.12) 1.09 (0.93–1.27)
HR multivariable-adjusted, model 2
c 1.47 (1.24–1.74) 0.99 (0.88–1.13) 1.0 0.99 (0.88–1.11) 1.02 (0.87–1.20)
HR multivariable-adjusted, model 3
d 1.33 (1.12–1.57) 0.96 (0.85–1.09) 1.0 0.97 (0.86–1.08) 0.97 (0.83–1.14)
HR multivariable-adjusted, model 4
e 1.31 (1.10–1.55) 0.96 (0.85–1.09) 1.0 0.96 (0.86–1.08) 0.97 (0.83–1.14)
Type 2 diabetes (cases/person-years) 62/9 282 161/36 006 330/78 263 199/47 561 89/13 276
Crude rate per 1000 person-years 6.7 4.5 4.2 4.2 6.7
HR model 1
b 1.44 (1.10–1.89) 1.04 (0.86–1.25) 1.0 0.97 (0.81–1.16) 1.24 (0.97–1.58)
HR multivariable-adjusted, model 2
c 1.36 (1.04–1.79) 1.02 (0.84–1.23) 1.0 0.95 (0.80–1.14) 1.16 (0.91–1.49)
HR multivariable-adjusted, model 3
d 1.08 (0.82–1.42) 0.94 (0.78–1.14) 1.0 0.92 (0.77–1.10) 1.04 (0.81–1.32)
HR multivariable-adjusted, model 4
e 1.06 (0.80–1.40) 0.94 (0.78–1.14) 1.0 0.92 (0.77–1.10) 1.05 (0.82–1.33)
Myocardial infarction (cases/person-years) 18/9 282 33/36 006 81/78 263 44/47 561 21/13 276
Crude rate per 1000 person-years 1.9 0.9 1.0 0.9 1.6
HR model 1
b 1.78 (1.07–2.97) 0.89 (0.59–1.34) 1.0 0.90 (0.62–1.30) 1.15 (0.70–1.89)
HR multivariable-adjusted, model 2
c 1.54 (0.92–2.59) 0.83 (0.55–1.24) 1.0 0.85 (0.59–1.24) 0.97 (0.59–1.62)
HR multivariable-adjusted, model 3
d 1.45 (0.87–2.44) 0.80 (0.53–1.20) 1.0 0.82 (0.56–1.19) 0.93 (0.56–1.55)
HR multivariable-adjusted, model 4
e 1.44 (0.85–2.43) 0.80 (0.53–1.20) 1.0 0.82 (0.56–1.19) 0.89 (0.54–1.49)
Stroke (cases/person-years) 17/9 282 29/36 006 55/78 263 44/47 561 24/13 276
Crude rate per 1000 person-years 1.8 0.8 0.7 0.9 1.8
HR model 1
b 2.32 (1.34–4.01) 1.14 (0.73–1.79) 1.0 1.23 (0.83–1.84) 1.84 (1.12–3.02)
HR multivariable-adjusted, model 2
c 2.20 (1.27–3.82) 1.15 (0.73–1.80) 1.0 1.19 (0.80–1.77) 1.69 (1.02–2.79)
HR multivariable-adjusted, model 3
d 2.12 (1.22–3.68) 1.13 (0.72–1.77) 1.0 1.16 (0.78–1.73) 1.62 (0.98–2.68)
HR multivariable-adjusted, model 4
e 2.06 (1.18–3.59) 1.13 (0.72–1.77) 1.0 1.16 (0.77–1.73) 1.65 (1.00–2.73)
Cancer (cases/person-years)
f 66/9 282 154/36 006 328/78 263 229/47 561 69/13 276
Crude rate per 1000 person-years 7.1 4.3 4.2 4.8 5.2
HR model 1
b 1.46 (1.12–1.91) 1.00 (0.83–1.21) 1.0 1.04 (0.88–1.23) 0.82 (0.63–1.06)
HR multivariable-adjusted, model 2
c 1.43 (1.10–1.87) 0.99 (0.82–1.20) 1.0 1.03 (0.87–1.23) 0.79 (0.61–1.04)
HR multivariable-adjusted, model 3
d 1.43 (1.09–1.87) 0.99 (0.82–1.20) 1.0 1.03 (0.87–1.22) 0.79 (0.60–1.03)
HR multivariable-adjusted, model 4
e 1.43 (1.09–1.87) 0.99 (0.82–1.20) 1.0 1.03 (0.87–1.22) 0.79 (0.60–1.03)
aType 2 diabetes, myocardial infarction, stroke, or cancer, whichever occurs first.
bStratified by age and adjusted for sex.
cAdditionally adjusted for sleeping disorders (yes/no), alcohol intake from beverages (non-consumers, men: .0–12 g/d, .12–24 g/d, .24 g/d; women: .0–6 g/d, .6–
12 g/d, .12 g/d), smoking status (never, former, current), walking, cycling, sports (hours/week), employment status (employed vs. unemployed), and education
(technical school or lower degree vs. university of applied sciences or university degree).
dAdjusted for the variables in model 2 plus potential mediators: BMI (kg/m
2), waist-to-hip ratio, prevalent hypertension at baseline (yes/no), and history of high blood
lipid levels at baseline (yes/no).
eAdjusted for the variables in model 3 plus consumption of caffeinated beverages (coffee and tea in g/day), satisfaction with life (4 levels: very satisfied, rather satisfied,
rather dissatisfied, very dissatisfied), satisfaction with health (4 levels: very satisfied, rather satisfied, rather dissatisfied, very dissatisfied), and intake of antidepressants
(yes/no).
fModel 3–4 for cancer includes the same covariable-set as models for type 2 diabetes, myocardial infarction, and stroke, except prevalent hypertension at baseline (yes/
no), and history of high blood lipid levels at baseline (yes/no).
doi:10.1371/journal.pone.0030972.t002
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inclusion of further covariates, especially smoking, but also alcohol
drinking, hypertension, and satisfaction with health, removed the
effect of sleep.
To our knowledge, this is the first study analyzing the
relationship between sleep duration and overall cancer risk
thereby observing an increased risk of developing cancer among
participants reporting ,6 h of sleep. Only a few studies examined
the association between short sleep duration and breast cancer
showing varying results. Kakizaki et al. found that women with
#6 h sleep are at increased risk of developing incident breast
cancer (HR=1.62, 95% CI: 1.05–2.50; p for trend=0.03) [24]
whereas results by other researchers indicate that a long sleep
duration of 9 h or more might have protective effects for breast
cancer risk [39,40]. On the contrary, data from the Nurses’ Health
Study does not support an inverse association of long sleep
duration and breast cancer risk [41]. Furthermore, these authors
called upon more research on the specific cancer sites and their
relation to sleep quantity or quality.
Biological mechanisms
A number of possible explanations for the association between
decreased sleep duration and chronic diseases can be discussed. Short-
term sleep deprivation induces inflammatory processes as well as an
activation of the sympathetic nervous system, increased blood
pressure, higher evening cortisol levels, and impaired glucose
tolerance [42,43,44,45,46,47] thus leading to an elevated risk of
cardiovascular diseases and diabetes. Moreover, short sleep was
shown to be related to increased levels of ghrelin, an appetite
stimulant, and decreased levels of leptin, a satiety factor, which
promotes appetite and food intake thereby leading to an increased risk
of obesity [10]. However, total energy intake or food intake did not
substantially differ across sleep categories in this cohort (see Table 1).
More research is necessary to examine the relationship between sleep
duration and food intake or meal patterns and meals contents.
Concerning cancer, current experimental and epidemiological
evidence supports a link between melatonin production and risk of
the development of cancer, especially breast cancer. Melatonin is a
pineal hormone that is involved in the circadian regulation and
facilitation of sleep, the inhibition of cancer development and
growth as well as the enhancement of immune function.
Individuals with short night sleep experience a suppression of
melatonin secretion. Thus, these individuals are more likely to
suffer from sleep disturbances, immune suppression and moreover
are at a higher risk of developing a number of different cancers
[11]. In addition, other mechanisms like inflammatory processes
or changes in the autonomous tone could possibly mediate the link
between sleep deficiency and cancer risk. Still, further research is
necessary to get advanced insight into the relationship between
sleep deficiency and cancer.
Long sleep and chronic diseases
In agreement with others, our study indicates that prolongation
of sleep above 9 h might be also not the best option. We found
that risk of stroke was also increased by 65% in persons reporting
long sleep duration ($9 h). Similar observations were made by
Chen et al. who found not only short sleep but also long sleep
duration to be associated with ischemic stroke in postmenopausal
women (HR=1.24, 95% CI: 1.04–1.47 and HR=1.70, 95% CI:
1.32–2.21 for women reporting 8 and $9 h of sleep) [21]. In
addition, an increased risk of stroke was observed only for those
sleeping more than 8 h in the First National Health and Nutrition
Examination Survey (NHANES-I) [27]. Previous studies suggest
that long sleep is further associated with an increased risk of
developing incident diabetes [15,16,25,26] which was not
confirmed by our study. Of note, these studies were less stringent
in excluding participants with chronic diseases at baseline which
could affect sleeping hours.
The association of long sleep with cardiovascular diseases like
stroke could be explained by poor sleep quality or poor health at
Figure 1. Association of sleep duration with overall chronic disease risk. Stratified by age and adjusted for sex, sleeping disorders, alcohol
intake from beverages, smoking status, walking/cycling/sports, employment status, education, BMI, waist-to-hip ratio, prevalent hypertension at
baseline, history of high blood lipid levels at baseline, consumption of caffeinated beverages, satisfaction with life, satisfaction with health, and intake
of antidepressants.
doi:10.1371/journal.pone.0030972.g001
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could lead to subsequent hypertension, or circulatory disturbances
in the brain, factors for which we could not control for in the
statistical analysis. Long sleep may therefore represent an
epiphenomenon of co-morbidity [48]. The positive association of
a long overall sleep duration per day with stroke is also reflected by
the association of daytime sleep and stroke among hypertensives
which might be responsible for this overall effect.
Daytime naps and chronic diseases
It is important to note that there had been effect modification by
prevalent hypertension at baseline regarding daytime sleep.
Among hypertensive persons reporting daytime naps the risk for
overall chronic disease, in particular stroke, tend to be increased;
whereas among non-hypertensive participants that stated to sleep
during the day the risk of overall chronic disease, primarily cancer,
is decreased.
This observation could be explained by a worse health
condition or relevant symptomatic sleep-related breathing disorder
(SRBD) among persons with hypertension reporting daytime sleep.
It has been shown that persons with poor health, pain, depression,
or those with poorer quality of sleep at night, e.g. by fragmented
sleep with elevated number of arousals, in general tend to have
daytime naps more frequently [49,50,51]. Therefore taking long
naps was found to be associated with higher morbidity and
mortality, especially among the elderly [17,28,52,53], which is in
line with our findings.
In contrast, short daytime naps among healthy persons might be
a part of good lifestyle or a result of good sleep hygiene with stress
relieving effects like it is making siesta in southern Europe
[52,54,55]. A nap of less than 30 min duration during the day
promotes wakefulness and alertness, reduces a sleep deficit and
enhances performance and learning ability. Thus, daytime sleeping
habits ingeneralcanreflectdifferent conceptsof lifestyle and health.
Table 3. Hazard ratios (HR) and 95% confidence intervals for daytime sleep and chronic diseases stratified by prevalent
hypertension.
Non-hypertensive participants Hypertensive participants
Daytime sleep No Yes No Yes
11 517 (90.4%) 1 223 (9.6%) 9 387 (86.3%) 1 493 (13.7%)
Overall chronic disease (cases/person-years)
a 604/91 920 85/9 618 1 080/71 959 273/10 890
Crude rate per 1000 person-years 6.6 8.8 15.0 25.1
HR model 1
b 1.0 0.82 (0.65–1.05) 1.0 1.22 (1.06–1.41)
HR model 2
c 1.0 0.77 (0.61–0.98) 1.0 1.21 (1.04–1.39)
HR model 3
d 1.0 0.75 (0.59–0.96) 1.0 1.13 (0.98–1.31)
Type 2 diabetes (cases/person-years) 178/91 920 24/9 618 521/71 959 118/10 890
Crude rate per 1000 person-years 1.9 2.5 7.2 10.8
HR model 1
b 1.0 0.85 (0.54–1.33) 1.0 1.22 (0.99–1.51)
HR model 2
c 1.0 0.81 (0.51–1.27) 1.0 1.21 (0.97–1.50)
HR model 3
d 1.0 0.77 (0.49–1.22) 1.0 1.05 (0.84–1.30)
Myocardial infarction (cases/person-years) 51/91 920 10/9 618 105/71 959 31/10 890
Crude rate per 1000 person-years 0.6 1.0 1.5 2.8
HR model 1
b 1.0 1.20 (0.58–2.49) 1.0 1.41 (0.92–2.17)
HR model 2
c 1.0 1.00 (0.47–2.12) 1.0 1.31 (0.84–2.04)
HR model 3
d 1.0 0.98 (0.46–2.09) 1.0 1.27 (0.82–1.98)
Stroke (cases/person-years) 36/91 920 9/9 618 95/71 959 29/10 890
Crude rate per 1000 person-years 0.4 0.9 1.3 2.7
HR model 1
b 1.0 1.27 (0.58–2.76) 1.0 1.60 (1.03–2.49)
HR model 2
c 1.0 1.12 (0.51–2.46) 1.0 1.54 (0.98–2.43)
HR model 3
d 1.0 1.10 (0.50–2.42) 1.0 1.51 (0.96–2.37)
Cancer (cases/person-years) 341/91 920 43/9 618 366/71 959 96/10 890
Crude rate per 1000 person-years 3.7 4.5 5.1 8.8
HR model 1
b 1.0 0.72 (0.52–1.00) 1.0 1.09 (0.86–1.38)
HR model 2
c 1.0 0.68 (0.49–0.95) 1.0 1.08 (0.85–1.38)
HR model 3
e 1.0 0.68 (0.49–0.95) 1.0 1.07 (0.84–1.37)
aType 2 diabetes, myocardial infarction, stroke or cancer, whichever occurs first.
bStratified by age and adjusted for sex.
cAdditionally adjusted for sleeping disorders (yes/no), sleep duration at night (,6, 6-,7, 7-,8, 8-,9, $9 h), alcohol intake from beverages (non-consumers, men: .0–
12 g/d, .12–24 g/d, .24 g/d; women: .0–6 g/d, .6–12 g/d, .12 g/d), smoking status (never, former, current), walking, cycling, sports (hours/week), employment
status (employed vs. unemployed), and education (technical school or lower degree vs. university of applied sciences or university degree).
dAdjusted for the variables in model 2 plus BMI (kg/m2), waist-to-hip ratio, and history of high blood lipid levels at baseline (yes/no).
eModel 3 for cancer includes the same covariates as models for type 2 diabetes, myocardial infarction and stroke, except history of high blood lipid levels at baseline
(yes/no).
doi:10.1371/journal.pone.0030972.t003
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The present study has a number of strengths including its
prospective nature, the large sample size, high rate of follow-up,
and verification of the self-reported information on disease
through medical reports [30].
Though, with a recruitment proportion of 22.7% of the
originally inquired persons, the EPIC-Potsdam cohort does not
present a representative sample of the general population. In most
studies, hence also in EPIC-Potsdam, the participating people are
more health-conscious than non-participating people. Comparison
to data from a representative health survey in eastern Germany
showed that study participants in EPIC-Potsdam are characterized
by a higher socio-economic status, higher health consciousness,
and a better health status than the general population in East
Germany [56].
One important methodological limitation of this study is the fact
that sleep duration was self-reported and measured only at study
recruitment. The Coronary Artery Risk Development in Young
Adults (CARDIA) study showed that subjective reports of habitual
sleep may be biased by systematic over-reporting among partici-
pants with short sleep durations compared to actigraph-measured
sleep [57]. However, other comparisons of subjective sleep duration
to the gold standard, polysomnography, or other more direct
assessments like actigraphy showed good correlations [58,59].
To increase validity of the results, it would be preferable to rely
on repeated objective assessment of sleep quantity and quality,
such as actigraphy [60] or even polysomnography [61], although
feasibility of such methods might be questionable in large-scale
cohort studies.
Another drawback of the EPIC study is that information on shift
work or individual sleep requirement is missing. Furthermore, our
question about the presence of any sleep disorder treated by a
physician can not be regarded as a valid medical diagnosis and
might underestimate the total prevalence of sleep disturbances. We
also do not have further information about sleep quality or specific
sleep disorders, like for example insomnia, sleep-disordered
breathing (snoring, sleep apnea), restless legs syndrome, hyper-
somnia, or parasomnia, which might mediate the relationship of
sleep and chronic diseases.
A further limitation is that all types of cancer were combined to
one endpoint due to small number of cases for single cancer sites in
this sample. However, in view of public health messages it is most
relevant to ask whether the overall risk of cancer is impacted by
sleep deprivation, independent of the type of cancer.
Conclusion
In conclusion, short sleep duration is a strong risk factor for
development of chronic diseases and thus is of significant public
health relevance as sleep habits are amenable to behavioral
interventions. This may be especially important in the context of
the reduced sleeping hours observed during the last decades.
However, compared to other lifestyle factors, e. g. nutrition,
smoking, or physical activity, sleep is less apparent to the public to
be a modifiable risk factor for chronic diseases. Therefore, it is
important to increase awareness of the importance of sleep among
health professionals and the lay public. Since short sleep is not only
a personal choice also the roots of sleep deprivation, for instance
shift work and prolonged working hours, should be addressed by
making changes in work patterns and access to sleep recovery
[7,8]. Future studies should explore the efficacy of sleep
interventions or rather changes in sleep habits for prevention of
chronic disease.
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a Type 2 diabetes, myocardial infarction, stroke or
cancer, whichever occurs first.
b Stratified by age and adjusted
for sex.
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